Benefits
Single small positive RT trial (n=16) showed strength benefit
A small RCT randomized 16 healthy men to resistance training (RT) alone or RT + ursolic acid 450 mg/day for 8 weeks. The UA group showed greater strength gains and elevated serum irisin (a myokine that activates browning of white fat). Limited by very small sample. Frequently cited but with substantial selection/multiple comparison concerns.
Larger trials failed to confirm muscle/strength benefits
A larger RCT in 54 healthy adults given 500 mg/day loquat leaf extract (delivering ~51 mg UA) for 12 weeks found NO differences in muscle strength, mass, or physical performance vs placebo. Another RCT in 22 active men on a high-protein diet + RT given 400 mg/day UA found NO additional effect on muscle strength or mass beyond what RT + protein achieved. Net: rigorous trials show NO meaningful effect on muscle outcomes.
Mouse data showed dramatic effects (poor translation to humans)
Mouse studies showed UA decreased adiposity, glucose intolerance, and fatty liver disease while increasing skeletal muscle mass and brown fat in diet-induced obese mice. Striking results drove massive clinical interest, but human translation has been disappointing. Possible reasons: poor oral bioavailability in humans, dose-effect mismatches, species-specific muscle anabolism mechanisms. Important reminder of the preclinical-clinical translation gap.
Anti-inflammatory and antioxidant effects (modest)
UA inhibits NF-κB, reduces TNF-α, IL-6, and COX-2 expression in vitro and animal models. Antioxidant via Nrf2 pathway activation. These mechanisms may underlie some claimed benefits in skin aging, cardiovascular health, and metabolic syndrome — though again, human RCT data are limited and mostly small.
Theoretical metabolic benefits (animal studies)
In animals, UA increased uncoupling protein 1 (UCP1) expression, brown fat mass, and energy expenditure — promising for obesity. A systematic review of 17 eligible studies on UA and adipose/muscle tissue concluded mechanistic effects are clear but human clinical translation is limited and inconsistent.
Mechanism of action
IGF-1/Akt/mTOR pathway activation (mouse muscle)
In mouse muscle, UA promotes hypertrophy via IGF-1 receptor signaling → Akt phosphorylation → mTORC1 activation → S6K1 → protein synthesis. It also suppresses atrophy genes (atrogin-1, MuRF-1). The pathway is real in mice; translation to humans appears blunted or absent at clinically achievable doses.
Brown fat induction via UCP1 (mouse)
UA increases brown adipose tissue (BAT) markers including uncoupling protein 1 (UCP1), triggering thermogenesis. Combined with skeletal muscle hypertrophy effect, drove obesity-prevention enthusiasm in animal models. Human BAT response to oral UA has not been demonstrated.
Irisin elevation (small human evidence)
UA + RT increased serum irisin levels — irisin is a myokine that promotes browning of subcutaneous white fat. The mechanistic chain UA → irisin → BAT browning is the most plausible link between mouse and human data, though replicate human studies are needed.
Anti-inflammatory: NF-κB inhibition
UA blocks IκB phosphorylation and degradation, preventing NF-κB nuclear translocation. Reduces TNF-α, IL-1β, IL-6 production. Mechanism comparable to many other anti-inflammatory triterpenes (boswellic acids, betulinic acid). Effects observable at concentrations achievable in inflamed tissues.
Clinical trials
Randomized controlled trial (Bang HS, Seo DY, Chung YM, Oh KM, Park JJ, Arturo F, Jeong SH, Kim N, Han J 2014, Korean J Physiol Pharmacol 18(5):441-446, doi:10.4196/kjpp.2014.18.5.441).
16 healthy male participants (mean age 29.4 years, BMI 27.1) randomly assigned to resistance training alone (RT n=7) or RT + UA (RT+UA n=9) for 8 weeks. UA dose 450 mg/day (3x150 mg).
RT+UA group showed greater strength gains, body fat reduction, and serum irisin elevation compared to RT-only group. Authors concluded UA + RT augments muscle strength via irisin pathway. Significant limitations: very small sample (n=16 total, 7 vs 9), short duration, single-center, no published replication. Frequently cited as the 'positive UA trial' but the evidence base is fragile.
Randomized double-blind placebo-controlled trial (Cho YH, Lee SY, Kim CM, Kim ND, Choe S, Lee CH, Shin JH 2016, Evid Based Complement Altern Med 2016:4374940, doi:10.1155/2016/4374940). NCT02401113.
54 healthy adults randomized to 500 mg/day loquat leaf extract (delivering 50.94 mg ursolic acid) or placebo for 12 weeks. Outcomes: peak torque/body weight at 60° knee extension, handgrip strength, skeletal muscle mass, physical performance, metabolic parameters at baseline, 4 weeks, 12 weeks.
NO differences in muscle strength, muscle mass, or physical performance between UA and placebo groups at any time point. Authors noted the dose may have been too low to observe effect. Counters small positive trials and is the largest, longest, most rigorous human UA trial to date with negative outcome on the primary muscle endpoints.
Double-blind placebo-controlled trial (Lobo PCB, Vieira IP, et al. 2020, Clin Nutr).
22 young men randomized to control + RT (CON, n=12, 400 mg/day placebo) or UA + RT (UA, n=10, 400 mg/day UA) for 8 weeks. Both groups consumed ~1.6 g/kg protein and performed identical RT program.
Both groups showed significant increases in body weight and BMI from training/diet effect. NO additional effect of UA on muscle strength or mass beyond what RT + high-protein diet alone achieved. Conclusion: 'Ursolic acid has no additional effect on muscle strength and mass in active men undergoing a high-protein diet and resistance training.' Most well-controlled trial with directly relevant population (RT + adequate protein) and clearly negative result.